Context: The BRAF V600E mutation is the most frequent genetic alteration in papillary thyroid carcinoma (PTC). In colorectal cancer, BRAF V600E was described to functionally cooperate with RAC1b, a hyperactive splice variant of the small GTPase RAC1, to sustain cell survival. This interplay has never been investigated in PTCs.
Introduction
Thyroid cancer is the most common endocrine malignancy and its incidence has increased worldwide over the last few decades (1, 2) . Papillary thyroid carcinoma (PTC) is the most frequent thyroid cancer, representing 75-85% of all cases (3) . While most PTC patients have a favorable prognosis, recurrence occurs in up to 40% of patients, and among these, some are at risk of cancer death (4, 5, 6) . Assessing a patient's risk for recurrence and/or death is, therefore, clinically relevant. Stratification risk mainly relies on clinical and histological data that in some cases appear to be inadequate. Identification of prognostic molecular markers could lead to a more adequate and individualized management and surveillance of PTC patients.
Activating mutations of several genes in the RET-RAS-BRAF-MEK-ERK pathway (MAP kinase pathway -MAPK) have been identified in the majority of PTCs (7, 8, 9) . BRAF and RAS point mutations as well as RET/PTC rearrangements are identified in more than 70% of PTCs (7) . Most often, these alterations are mutually exclusive (7, 8, 9, 10) . BRAF V600E mutation is the most frequent genetic alteration in PTCs, occurring in 29-83% of cases (8, 9, 11) . BRAF is a serine/threonine kinase of the RAF family of proteins and is a critical effector of the MAPK pathway, which mediates cellular response to various growth signals (12) . The V600E mutation constitutively activates BRAF kinase, leading to prolonged stimulation of the MAPK pathway, which ultimately leads to uncontrolled cell proliferation and faulty apoptosis (8, 9, 12) . The majority of studies have associated BRAF V600E mutation with a more aggressive PTC behavior, whereas a few studies failed to reproduce this finding (13, 14, 15, 16, 17, 18, 19, 20, 21, 22) . Still, its value as a prognostic marker remains incompletely established and other players might be implicated, justifying the search for additional molecular markers.
BRAF V600E mutation has been implicated in a number of human cancers, including melanoma, sarcomas, and colorectal carcinoma (12) . In a subset of colorectal tumors, cell survival depends on a functional cooperation between mutant BRAF V600E and the overexpression of RAC1b, which is a splice variant of RAC1 (23) .
RAC1 is a member of the Rho family of small GTPases that regulate cellular functions by cycling between an inactive, GDP-bound and an active, GTP-bound state, the latter allowing their interaction with effectors such as protein and lipid kinases (24) . The splice variant, RAC1b, contains 57 additional nucleotides that result in an in-frame insertion of 19 amino acid residues in the vicinity of an important regulatory region of the GTPase (25) . It was first identified in skin and epithelial tissue of the intestinal tract (26) . RAC1b expression was also documented in breast tissue and was found to be overexpressed in colorectal and lung cancer (23, 26, 27, 28) .
Comparative to RAC1, RAC1b has unique properties (29, 30, 31, 32, 33, 34) , exists predominantly in the GTP-bound active form (due to an accelerated GDP/GTP exchange activity and a decreased rate of GTP hydrolysis) (29, 30, 31) , and favors specific pathways conducting to the production of reactive oxygen species (ROS) and NF-kB activation (29, 32, 33, 34) . Increased cellular ROS causes oxidative damage and induce genomic instability, stimulating carcinogenesis (33) . The activation of the NF-kB pathway initiates an antiapoptotic transcriptional response and promotes cell cycle progression (32, 34) .
Rac1b has been shown to sustain tumor cell survival in colorectal cancer (35) and to mediate epithelialmesenchymal transition (EMT), via a mechanism dependent on both RAC1b-induced ROS and matrix metalloproteinase 3 (MMP3), in mouse mammary epithelial cells (33) . Uncontrolled proliferation and EMT are ultimately involved in the development of tumor formation, invasion, and metastases (36) . The RAC1b tumorigenic properties and its functional cooperation with BRAF V600E to sustain colorectal tumor cell survival led us to investigate whether RAC1b was expressed in PTCs.
Materials and methods

Patient samples
Sixty-one samples representative of primary tumors from a cohort of 61 PTC patients (mean age of 41 years; F:M ratio 42:19) who underwent partial/total thyroidectomy in our institution from 2000 to 2008 (Table 1 ) and 26 samples corresponding to normal thyroid tissue were analyzed. Samples were collected at surgery and immediately frozen and stored in liquid nitrogen. In 23 cases, it was possible to pair tumors with their normal adjacent tissue or contralateral lobe (normal paired sample -NPS). Tissue sample collection was carried out in accordance with protocols approved by the institutional review board and informed consent was obtained for the study together with the consent for surgery.
RNA extraction and cDNA synthesis
Total RNA was obtained from frozen tissues using RNA easy kit (Qiagen), according to manufacturer's instructions, and 2 mg were reverse transcribed using random primers and SuperScript II (Invitrogen).
Screening for BRAF V600E mutation and RAC1/RAC1b amplification Screening for BRAF V600E oncogenic mutation was conducted by direct sequencing, as previously described (37) . Primers for specific amplification of RAC1 and RAC1b were Rac1/1bF (5 0 -atgttatggtagatggaaaaccg) and Rac1/1bR (5 0 -cggacattttcaaatgatgcagg), generating PCR products of 154 and 211 bp, allowing the distinction between the two splice variants. GAPDH was used as an endogenous control in RT-PCR experiments; primers for specific amplification of GAPDH were GH1 (5 0 -cgtcttcaccaccatggagaa) and GH3 (5 0 -gaggcagggatgatgttctg), generating a PCR product of 330 bp.
QRT-PCR
The RAC1b, total RAC1, and GAPDH expression levels were quantified by QRT-PCR on an ABI Prism 7900HT Sequence Detection System using specific primers and TaqMan probes from the Assay_on_Demand products (Hs00251654_ml (selectively amplifies Rac1b), Hs01902432_sl (amplifies both Rac1 variants), and 4326317E (amplifies human GAPDH); Applied Biosystems) according to manufacturer's instructions. cDNA samples were diluted 20 times and 4 ml were used in each real-time PCR. Amplification reactions were performed in triplicate for each sample. RAC1b levels were normalized to total RAC1 (RAC1bC RAC1) expression level. For each sample, RAC1b normalized values were then expressed relative to RAC1b expression level of a pool of normal thyroid tissues, used as reference sample. Expression values correspond to arbitrary units representing fold differences relative to the reference sample. Similarly, total RAC1 levels were normalized to GAPDH expression level (housekeeping gene normalization) and expressed relative to total RAC1 expression level of the reference sample.
Protein lysates, SDS-PAGE, and western blotting
Total protein lysates were prepared from frozen thyroid tissues (PTC and corresponding NPS). Tissue samples were disintegrated without thawing and immediately solubilized in an appropriate volume (ten times the tissue wet weight) of SDS-extraction buffer (40 mM Tris-HCl, pH 6.8, 5% glycerol, 2% SDS, 100 mM dithiothreitol, and 1 U/ml Benzonase).
Protein lysates were resolved, according to standard protocols, in 10% SDS-PAGE and transferred to PVDF membranes (Bio-Rad). Membranes were probed using 
www.eje-online.org Table 1 Continued mouse monoclonal anti-b-actin (Sigma) at 1:3000 dilution, rabbit polyclonal anti-RAC1b (EMD Millipore Bioscience, Billerica, Massachusetts, United States) at 1:1000 dilution, or mouse monoclonal anti-RAC1 (Upstate, EMD Millipore Bioscience, Billerica, Massachusetts, United States) at 1:500 dilution. Detection was carried out using secondary peroxidase-conjugated anti-mouse IgG (Bio-Rad) or anti-rabbit IgG (Bio-Rad) antibodies followed by chemiluminescence.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism statistical software (San Diego, CA, USA 
Results
RAC1b is expressed in thyroid tissue
RT-PCR analysis of total RNA from representative PTCs and corresponding NPS (Fig. 1A and B ) revealed the expression of both RAC1 (154 bp) and RAC1b (211 bp). Compared with normal thyroid tissue, the expression of Rac1b was higher in most tumoral tissues.
RAC1b is overexpressed in PTC
A quantitative real-time RT-PCR approach was then used to access RAC1b expression levels in 23 PTCs and corresponding NPSs. Paired analysis disclosed a significantly higher RAC1b expression among PTCs vs NPSs: 1.23G0.52 vs 0.79G0.26 (PZ0.0001 -Wilcoxon signed rank test) ( Fig. 2A) . Moreover, the mean fold increase of RAC1b expression in PTCs, comparative to the corresponding NPSs, was 1.5G0.6 (range: 1.4-3.3). This quantitative analysis was then extended to the total of tumor (nZ61) and normal (nZ26) samples (mean expression levels of 1.26G0.56 and 0.81G0.26 respectively; P!0.0001 -unpaired Student's t-test), thus reinforcing overexpression of RAC1b in PTCs (Fig. 2B) .
Expression levels of GAPDH were also tested by qPCR. After GAPDH normalization, no significant differences, in total RAC1 levels, were found between normal and tumor samples (mean expression levels of 1.5G0.81 vs GAPDH was used to monitor input cDNA levels.
RAC1b is overexpressed in PTC 799 EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013) 168 www.eje-online.org 1.4G0.80; PZ0.39 -unpaired Student's t-test), allowing to conclude that the higher levels of RAC1b found in tumors were not due to total RAC1 downregulation.
In order to make a distinction between PTCs that overexpressed RAC1b from those that did not, we defined a threshold level of expression above which we considered RAC1b to be overexpressed. We set the threshold value at 1.32, which corresponds to the mean plus two S.D. of the RAC1b expression level in the normal thyroid group (Fig. 2B) . Based on this threshold, 28 out of 61 PTCs (46%) were found to overexpress RAC1b. RAC1b overexpression correlates with BRAF V600E mutation BRAF V600E mutation was present in 27 out of 61 (44%) PTCs (Fig. 2B) . A significant correlation (PZ0.0008, two-tailed Fisher's exact test) between the presence of BRAF V600E and RAC1b overexpression was identified: 19 out of 28 (68%) RAC1b overexpressing PTCs were also BRAF V600E positive. In contrast, only eight out of 33 (24%) PTCs without RAC1b overexpression presented this oncogenic mutation (Fig. 2C ).
RAC1b overexpression is associated with poor clinical outcome
To investigate whether there was a correlation between RAC1b overexpression and clinical outcome, patients were divided into two groups (Table 1) based on the analysis of longitudinal evolution and final outcome (mean follow-up of 6 years; range 0-12 years). Group I (64% of patients) included patients who reached full sustained remission and those presenting stable residual values of serum thyroglobulin !5 ng/ml, in the absence of antithyroglobulin antibodies (biochemical disease), without clinical or imagiological evidence of disease, after initial treatment. Group II (36% of patients) included patients with persistence of disease after primary treatment, patients with at least one relapse (despite subsequent remission), and those who died from disease.
Despite the absence of correlations between histopathological parameters (such as multifocality, vascular invasion, lymph node metastases or extrathyroidal invasion) and RAC1b overexpression, the presence of BRAF V600E mutation, or the coexistence of both (Table 2) , comparison between groups disclosed a higher prevalence of RAC1b overexpression within group II (PZ0.0029, two-tailed Fisher's exact test). RAC1b overexpression was observed in 73% (16 out of 22) of group II patients, whereas in group I, overexpression was present in only 31% of cases (12 out of 39) (Fig. 3A) . On the contrary, there was no significant difference in the frequency of BRAF V600E mutation between groups (PZ0.2865, two-tailed Fisher's exact test) (Fig. 3B) . Also worth mentioning is the fact that all BRAF V600E-positive cases in group II exhibited RAC1b overexpression whereas all BRAF V600E-positive tumors that did not overexpress RAC1b were in group I (Fig. 3C and D) . RAC1b overexpression observed at RNA level was confirmed at protein level, by western blot analysis of a β- Actin   Group II   T1 N1  T2 N2  T3 N3 T4 N4  T5 N5 T6 Table 1 ). Whereas RAC1b protein levels were clearly increased in group II tumors over the corresponding NPS, this difference was not observed in the cases analyzed from group I (Fig. 4) .
Discussion
Risk stratification of PTC patients based on clinicopathological criteria is often unreliable to tailor case management to individual risk levels. The prognostic value of the BRAF V600E mutation in PTC patients has been an object of extensive studies. While many studies report an association of BRAF V600E mutation with a more aggressive behavior (13, 16, 17, 20, 22) , others, including the present series, failed to document such association (14, 18, 19, 21) . These apparently conflicting results have to be reevaluated in light of a recent study (38) demonstrating that clonal occurrence of BRAF mutation is a rare event in PTC and that more frequently this mutation affects only a subpopulation of cells. Additional alterations might be necessary to sustain transformation in BRAF V600E-positive tumors. The finding that BRAF V600E and RAC1b functionally cooperate to sustain colorectal cell viability (23) made us to consider this hypothesis in PTCs.
Results clearly showed, for the first time, that thyroid tissues express RAC1b. Moreover, we observed that Rac1b was overexpressed in PTCs (classical variant -59%, follicular variant -25%) and found a striking correlation between poor clinical outcome and RAC1b overexpression (PZ0.0029). It is worthy to note that, despite the lack of association between BRAF V600E mutation and clinical outcome, the majority of RAC1b overexpressing PTCs from the group with poorer outcome were also positive for BRAF V600E (12 out of 16; 75%).
RAC1b overexpression significantly associates with BRAF V600E mutation (PZ0.0008) and co-detection of Rac1b overexpression and BRAF V600E (Fig. 3C ) was significantly associated with poor clinical outcome (PZ0.0044). This suggests that the reported functional cooperation between these two factors in colorectal cancer may also play an important role in thyroid malignancies.
The exact role of RAC1b in thyroid tumorigenesis requires further investigation. However, it is conceivable that, similar to what was documented for colorectal cancer cells (23) , the association of RAC1b with BRAF V600E might synergize to sustain the proliferation and survival of thyroid cancer cells. Although activating alterations in the canonical Ras/Raf/MEK/ERK oncogenic pathway are considered to have a key role in thyroid carcinogenesis, similar to what was recently suggested for the Rap1 GTPase (39), activation of RAC1b selective signaling may trigger additional pathways contributing to PTC progression (Fig. 5) . Moreover, RAC1b overexpression has been implicated in the induction of EMT (40, 41) . EMT is a form of epithelial plasticity that has been associated with tumor metastasis and, accordingly, RAC1b was reported to have a key role in the malignant progression of breast and lung tumors (28, 36, 41) . Our finding that RAC1b overexpression significantly associates with a poor outcome in PTCs may be indicative of a similar role for RAC1b in the progression of thyroid carcinomas.
In sum, present findings point to an important role of RAC1b in PTC development. After further validation, it may be a novel and useful marker for predicting the clinical outcome of PTC patients. Moreover, present data provide new insights for clarifying past discrepancies concerning BRAF V600E mutation and its impact on the clinical course of PTC patients.
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